

Ref: NLL/CS/2025- 574

September 16, 2025

To,

1. National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051

Symbol: NECLIFE

2. BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001

Scrip Code: 532649

Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations").

Sub.: Slump Sale of business of manufacture, distribution, marketing and sale of active pharmaceutical ingredients and formulations ("Slump Sale") to Ceph Lifesciences Private Limited ("Purchaser")

Dear Sir/ Madam,

This is in continuation of disclosures regarding the Slump Sale provided vide letter no. NLL/CS/2025-514 dated July 07, 2025 and Annexure 1 thereof.

In this regard, please be informed that Nectar Lifesciences Limited and the Purchaser have mutually agreed to extend the expected date of completion of the Slump Sale to on or before October 20, 2025.

The other relevant disclosures, regarding the Slump Sale, has already been provided as per Annexure no. 1 vide letter no. NLL/CS/2025-514 dated July 07, 2025, Notice of Extraordinary General Meeting ("EGM") dated July 07, 2025, addendum to Notice of EGM dated July 23, 2025 and outcome of EGM vide letter no. NLL/CS/2025- 533 dated August 04, 2025.

This is for your information and records please.

Thanking you,

Yours faithfully

For **Nectar Lifesciences Limited**

(Sanjaymohan Singh Rawat)

Company Secretary & Compliance Officer